CTOs on the Move

Ciitizen

www.ciitizen.com

 
Ciitizen is a platform that helps you collect, organize, and share your medical records digitally. Use it to get a second opinion, coordinate with a caregiver, and donate to research.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Ciitizen raised $17M on 01/16/2019

Similar Companies

MitoSciences Inc

MitoSciences Inc is a Eugene, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

LamdaGen Corp

LamdaGen Corp is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Hookipa Pharma

Hookipa Pharma Inc. (NASDAQ: HOOK) is a clinical stage biopharmaceutical company developing a new class of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body`s immune system. HOOKIPA`s proprietary arenavirus-based technologies, VaxWave®*, a replication-deficient viral vector, and TheraT®*, a replication-attenuated viral vector, are designed to induce robust antigen specific CD8+ T cells and pathogen-neutralizing antibodies. Both technologies are designed to allow for repeat administration while maintaining an immune response. TheraT® has the potential to induce CD8+ T cell response levels previously not achieved by other published immuno-therapy approaches. HOOKIPA`s “off-the-shelf” viral vectors target dendritic cells in vivo to activate the immune system. HOOKIPA`s VaxWave®-based prophylactic cytomegalovirus vaccine candidate is currently in a Phase 2 clinical trial in patients awaiting kidney transplantation from living cytomegalovirus-positive donors. To expand its infectious disease portfolio, HOOKIPA has entered into a collaboration and licensing agreement with Gilead Sciences, Inc. to jointly research and develop functional cures for HIV and Hepatitis B infections. HOOKIPA is building a proprietary immuno-oncology pipeline by targeting virally mediated cancer antigens, self-antigens and next-generation antigens.

Singlera Genomics

Singlera Genomics Inc., a fast growing company focusing on non-invasive genetic testing, was co-founded in July 2014 in San Diego, California by Professor Yuan Gao (Johns Hopkins University), Professor Kun Zhang (University of California at San Diego), Mr. Jiangli Zhang (CEO), Mr. Qiang Liu (COO), and Dr. Rui Liu (CTO). The company currently has an R&D center in La Jolla, California, and a business and clinical operation site in Shanghai, China. Singlera has proprietary technologies in single cell sequencing, DNA methylation and bioinformatics. In the past decade, Professor Gao, Professor Zhang and Dr. Liu have made outstanding achievements in their respective scientific research fields, and have published hundreds of research papers in top level scientific journals. These publications include 20+ papers in Cell, Nature, and Science. In recent years Professor Gao, Professor Zhang, and Dr. Liu have expanded their efforts to translational diagnostics, and have applied their expertise to develop genetic tests. Singlera is committed to the application of Next Generation Sequencing technologies, to diagnose genetic diseases and disorders. Singlera`s main products and services include tumor diagnosis and personalized treatment, non-invasive prenatal diagnosis, pre-implantation genetic screening, and customized scientific research services. Singlera is dedicated to the development of precision medicine, striving to help the patients through early, accurate and informative diagnoses.

Quincy Bioscience

Quincy Bioscience is a Madison, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.